

4902616

**PROCESS FOR THE
PREPARATION OF CAPSULAR
POLYSACCHARIDES OF
STAPHYLOCOCCI, THE
POLYSACCHARIDES OBTAINED,
USES OF THESE
POLYSACCHARIDES AND
STRAINS FOR CARRYING OUT
OF THE PROCESS**

Jean-Michel Fournier, Anne Bouvet, Alain Boutonnier, Paris, France assigned to Institut Pasteur

The subject of the invention is a process for the preparation of capsular polysaccharides characteristic of *Staphylococcus aureus*, comprising the use of coagulase-negative strains of staphylococci for the preparation of these polysaccharides. The capsular polysaccharides obtained can be used for the preparation of vaccines against *Staphylococcus aureus* and diagnostic agents.

4902618

**PRODUCTION OF HYBRIDOMA
ANTIBODIES FOR INTERFERON**

Kurt F Berg, Gentofte, Denmark assigned to Wadley Technologies Inc

A hybridoma continuous cell line, capable of producing monoclonal antibodies specific for all species of human interferon-alpha, is disclosed. A method for producing hybridomas and monoclonal antibodies with the required specificity is also disclosed. Methods of use of the disclosed compositions for purifying human interferon-alpha, screening blood in blood banks, and for producing specific polyclonal antibodies are claimed and detailed.

4902623

PLASMINOGEN ACTIVATOR

Eugene B D Dowdle, Cape Town, South Africa assigned to South African Inventions Development Corporation

For selectively and reversibly adsorbing tPA, pro-tPA or mixtures thereof, from an aqueous medium, for example, derived from a melanoma

cell culture, the aqueous medium is intimately contacted with an affinity reagent comprising an immobilized Kunitz-type inhibitor, substantially as occurs in and is extractable from seeds of an *Erythrina* species, e.g., *Erythrina latissima*, having *Erythrina* species, the following combination of characteristics: (a) it is an inhibitor of the Kunitz-type; (b) it inhibits trypsin; (c) it inhibits plasmin; (d) it has no effect on urokinase; (e) it inhibits tPA; and (f) in its immobilized form, it is a selected adsorbent for tPA and its precursor pro-tPA, to thereby cause the tPA, pro-tPA or mixtures thereof to become selectively adsorbed on the affinity reagent.

4904468

**CANINE CORONAVIRUS
VACCINE**

Michael Gill, Stephen May assigned to Norden Laboratories Inc

A vaccine for protecting canine animals from disease caused by infection with canine coronavirus (CCV) which comprises an effective amount of the cell-associated CCV peplomer protein. A polyvalent vaccine comprising an effective amount of cell-associated CCV peplomer protein and an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed.

4904481

**METHOD OF CONFERRING
IMMUNO-TOLERANCE TO A
SPECIFIC ANTIGEN**

C Garrison Fathman assigned to The Board of Trustees of Leland Stanford University

A method of selectively suppressing the immune system and conferring immunotolerance against a specific antigen by interferring with the L3T4 differentiation antigens on helper T cells is described. Simultaneous administration of a binding moiety specific for the L3T4-equivalent in the subject species and a specific antigen or administration of the antigen subsequent to the binding moiety for L3T4-equivalent within the time required for T-cell recovery results in a diminished ability of the subject to respond immunologically to the antigen, whether or not the subject has been exposed previously to the antigen.